Similar articles

• Rituximab and its use in autoimmune bullous disorders.

  Daniel BS, Murrell DF, Joly P. Daniel BS, et al. Dermatol Clin. 2011 Oct;29(4):571-5. doi: 10.1016/j.det.2011.06.023. Dermatol Clin. 2011. PMID: 21925000
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.

  Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K. Furst DE, et al. Ann Rheum Dis. 2011 Mar;70 Suppl 1:i2-36. doi: 10.1136/ard.2010.146852. Ann Rheum Dis. 2011. PMID: 21339216 No abstract available.
• [Biotherapies to treat necrotizing vasculitis].

  Guillevin L. Guillevin L. Rev Med Interne. 2010 Dec;31 Suppl 3:S304-6. doi: 10.1016/j.revmed.2010.10.001. Epub 2010 Nov 4. Rev Med Interne. 2010. PMID: 21055849 French. No abstract available.
• Biological therapies in rheumatic diseases.

  Conti F, Ceccarelli F, Massaro L, Cipriano E, Di Franco M, Alessandri C, Spinelli FR, Scrivo R. Conti F, et al. Clin Ter. 2013;164(5):e413-28. doi: 10.7417/CT.2013.1622. Clin Ter. 2013. PMID: 24217844 Review.
• Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.

  Ramos-Casals M, García-Hernández FJ, de Ramón E, Callejas JL, Martínez-Berriotxoa A, Pallarés L, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, Pérez-Alvarez R, Micó ML, Medrano F, Gómez de la Torre R, Díaz-Lagares C, Camps M, Ortego N, Sánchez-Román J; BIOGEAS Study Group. Ramos-Casals M, et al. Clin Exp Rheumatol. 2010 Jul-Aug;28(4):468-76. Epub 2010 Aug 30. Clin Exp Rheumatol. 2010. PMID: 20525449